Cadrenal Therapeutics, Inc. Common Stock logo

Cadrenal Therapeutics, Inc. Common Stock(CVKD)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 8 days
PROFIT SINCE LAST BUY
+17.24% ▲
LAST CLOSE
$1.7
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CVKD

11/20/2026: CVKD (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Cadrenal Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for life-threatening cardiovascular and thrombotic conditions. Its primary investment appeal centers on its lead Phase 3-ready candidate, CAD-1005, which targets heparin-induced thrombocytopenia under FDA Orphan Drug status. Key strengths include promising clinical data and clear regulatory alignment, though the company remains pre-revenue and dependent on external financing. Primary risks involve clinical trial execution, binary regulatory outcomes, and the need for ongoing capital raises. The stock suits risk-tolerant investors seeking biotechnology growth exposure, with key developments hinging on clinical trial progress and strategic partnering initiatives.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high-growth potential driven by clinical pipeline milestones, though it carries substantial binary clinical risk.
Momentum investorStrong fit while signal remains positiveShort-term momentum can spike dramatically around clinical catalysts, regulatory updates, or strategic partnership announcements.
Value investorWeak fitAs a pre-revenue clinical-stage biotech with ongoing cash burn, traditional value metrics such as earnings or P/E ratios are inapplicable.
Dividend investorWeak fitThe company pays no dividends and retains all capital to fund research and clinical trials.
Low-risk investorWeak fitHigh share price volatility and binary clinical trial outcomes expose investors to significant capital loss risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap clinical biotech stocks experience sharp price fluctuations based on news flow, funding updates, and market sentiment.
Valuation riskMedium / highValuation is heavily speculative and tied to future clinical trial success rather than current earnings.
Competition risk (specialized biopharma & anticoagulant therapies)Medium / highThe company faces indirect competition from larger pharmaceutical pipelines targeting overlapping cardiovascular indications.
Business qualityMediumThe pipeline shows scientific promise with orphan drug designations, but the company lacks commercial revenue operations.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess relies entirely on successfully executing clinical trials, securing funding, and navigating complex regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 7.01M USD
Price to earnings Ratio -
1Y Target Price 14
Price to earnings Ratio -
1Y Target Price 14
Volume (30-day avg) 134.3K shares
Beta 1.96
52 Weeks Range 0.82 - 12.50
Updated Date 11/20/2026
52 Weeks Range 0.82 - 12.50
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.67

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 226.91%
Avg. Invested days 34
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CVKD receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CVKD has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-24.3%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
CVKD's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
CVKD's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-24.3%, negative) and free-cash-flow growth (-71.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 10.1% and approximately 90.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 15.64% supports management-shareholder alignment.

Top 5 Institutional Investors

Vanguard Capital Management, LLC 1.41%
HRT FINANCIAL LLC 0.81%
Vectors Research Management, LLC 0.56%
Geode Capital Management, LLC 0.53%
Vanguard Fiduciary Trust Co 0.23%

Unit Economics (Per $1K Revenue)

★★★★★
CVKD generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CVKD has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Development & Potential LicensingCurrently pre-revenue, future monetization is anticipated through commercial product sales, out-licensing agreements, or corporate partnerships.The company does not sell commercial products yet and relies on capital raises and potential partnering deals to fund operations.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 4.03M
Price to Sales(TTM) -
Enterprise Value 4.03M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.21
Shares Outstanding 4.12M
Shares Floating 3.72M
Shares Outstanding 4.12M
Shares Floating 3.72M
Percent Insiders 15.64
Percent Institutions 10.12

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.